Grifols/$GRFS
1D1W1MYTD1Y5YMAX
About Grifols
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
- Ticker
- $GRFS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 25,258
- Headquarters
- Barcelona, Spain
- Website
- www.grifols.com
Grifols Metrics
BasicAdvanced
$6.9B
10.12
$0.76
1.19
$0.09
1.97%
Price and volume
Market cap
$6.9B
Beta
1.19
52-week high
$10.23
52-week low
$6.96
Average daily volume
584K
Dividend rate
$0.09
Financial strength
Current ratio
2.373
Quick ratio
0.697
Long term debt to equity
110.376
Total debt to equity
117.243
Dividend payout ratio (TTM)
28.32%
Interest coverage (TTM)
2.23%
Profitability
EBITDA (TTM)
1,804.919
Gross margin (TTM)
37.79%
Net profit margin (TTM)
6.09%
Operating margin (TTM)
18.18%
Effective tax rate (TTM)
19.16%
Revenue per employee (TTM)
$335,690
Management effectiveness
Return on assets (TTM)
4.23%
Return on equity (TTM)
6.93%
Valuation
Price to earnings (TTM)
10.119
Price to revenue (TTM)
0.616
Price to book
1.07
Price to tangible book (TTM)
-1.15
Price to free cash flow (TTM)
7.126
Free cash flow yield (TTM)
14.03%
Free cash flow per share (TTM)
1.085
Dividend yield (TTM)
1.11%
Forward dividend yield
1.97%
Growth
Revenue change (TTM)
-0.33%
Earnings per share change (TTM)
46.08%
3-year revenue growth (CAGR)
4.63%
10-year revenue growth (CAGR)
6.41%
3-year earnings per share growth (CAGR)
329.35%
10-year earnings per share growth (CAGR)
-1.77%
What the Analysts think about Grifols
Analyst ratings (Buy, Hold, Sell) for Grifols stock.
Grifols Financial Performance
Revenues and expenses
Grifols Earnings Performance
Company profitability
Grifols News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.